Genocea Biosciences, Inc.(GNCA)

Description: Genocea Biosciences, Inc., a clinical stage biotechnology company, discovers and develops novel vaccines to treat infectious diseases. The company, through its proprietary discovery platform, AnTigen Lead Acquisition System (ATLAS), designs vaccines that stimulate T cell immunity. The company primarily develops GEN-003, a candidate therapeutic vaccine or immunotherapy, which is in Phase 1/2a trial to treat herpes simplex virus-2 or HSV-2 infections; and GEN-004, a T cell vaccine candidate that is in Phase 1 trial to prevent infections caused by pneumococcus. It also develops earlier-stage programs for chlamydia, HSV-2 prophylaxis, and malaria. The company, formerly known as Genocea, Inc., was founded in 2006 and is headquartered in Cambridge, Massachusetts.

---

Keywords: Biotechnology Infectious Diseases Immunotherapy Infection Vaccines Vaccination Microbiology Viruses Malaria Herpes Sexually Transmitted Diseases And Infections Herpes Simplex Herpes Simplex Virus Immunity Herpes Simplex Research Chlamydia

---

Home Page: www.genocea.com

GNCA Technical Analysis

100 Acorn Park Drive
Cambridge, MA 02140
United States
Phone: 617 876 8191

---

Officers

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)